155 Results for "

ABL kinase

" in MedChemExpress (MCE) Product Catalog:
Products (155)

155 Results for "ABL kinase" in MCE Product Catalog:

127
127 Publications Verification
Cat. No.: HY-15463
CAS No.: 152459-95-5
Purity:  99.95%
Synonyms: STI571; CGP-57148B
Research Areas:  

Cancer

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
127
127 Publications Verification
Cat. No.: HY-50946
CAS No.: 220127-57-1
Synonyms: STI571 Mesylate; CGP-57148B Mesylate
Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
loading...
    loading...
66
66 Cited Publications
Cat. No.: HY-15150
CAS No.: 1037624-75-1
Purity:  99.92%
Synonyms: R428; BGB324
Target:  

TAM Receptor

Research Areas:  

Cancer

Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
loading...
    loading...
56
56 Cited Publications
Cat. No.: HY-12047
CAS No.: 943319-70-8
Purity:  99.67%
Synonyms: AP24534
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .
loading...
    loading...
56
56 Cited Publications
Cat. No.: HY-108766
CAS No.: 1114544-31-8
Purity:  99.76%
Synonyms: AP24534 hydrochloride
Research Areas:  

Infection Cancer

Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-10159
CAS No.: 641571-10-0
Purity:  99.94%
Synonyms: AMN107
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-10159A
CAS No.: 923288-90-8
Purity:  99.91%
Synonyms: AMN107 monohydrochloride monohydrate
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against BCR-ABL, and is active against many BCR-ABL mutants.
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-10159C
Synonyms: AMN107 hydrochloride dihydrate
Target:  

Autophagy Bcr-Abl

Research Areas:  

Cancer

Nilotinib (AMN107) hydrochloride dihydrate is an orally active Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-10159B
CAS No.: 923288-95-3
Synonyms: AMN107 hydrochloride
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib (AMN107) hydrochloride is an orally active Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-10158
CAS No.: 380843-75-4
Purity:  99.89%
Synonyms: SKI-606
Target:  

Src Bcr-Abl Autophagy

Research Areas:  

Cancer

Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-10158A
CAS No.: 918639-08-4
Purity:  99.97%
Synonyms: SKI-606 hydrate
Target:  

Src Bcr-Abl

Research Areas:  

Cancer

Bosutinib hydrate is an oraly activel Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-50868
CAS No.: 859212-16-1
Synonyms: INNO-406; NS-187
Target:  

Bcr-Abl Src Apoptosis

Research Areas:  

Cancer

Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph + leukemia cells. Bafetinib has antitumor activity .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-13024
CAS No.: 1020172-07-9
Purity:  99.91%
Synonyms: DCC-2036
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC50 values of 0.8 nM and 4 nM against Abl1 WT and Abl1 T315I, respectively. Rebastinib potently inhibits CYP2C8 (IC50 = 0.0533 μM) and CYP2C9 (IC50 = 2.54 μM). Rebastinib allosterically inhibits Tie2 with an IC50 of 0.63 nM. Rebastinib inhibits the transcriptional activity of FoxO1. Rebastinib inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib induces Apoptosis. Rebastinib exerts anti-tumor activity in breast cancer. Rebastinib exerts anti-angiogenic effects. Rebastinib increases myotube diameter and improves reduced contractility. Rebastinib can be used in research related to triple-negative breast cancer, luminal breast cancer, pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-50514
CAS No.: 896466-04-9
Research Areas:  

Cancer

AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-10339
CAS No.: 1000669-72-6
Purity:  99.91%
Research Areas:  

Cancer

KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABL T315I and Aurora kinase with IC50s of 6.6, 14, 4 and 48 nM, respectively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-15749
CAS No.: 898280-07-4
Purity:  99.64%
Research Areas:  

Endocrinology Cancer

XL228 is a multi-targeted tyrosine kinase inhibitor with IC50s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and Lyn, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13941
CAS No.: 221243-82-9
Purity:  98.96%
Synonyms: 1-NA-PP 1
Target:  

Src PKD

1-Naphthyl PP1 (1-NA-PP 1) is a selective inhibitor of src family kinases and Protein Kinase D. 1-Naphthyl PP1 inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13941B
CAS No.: 956025-47-1
Purity:  99.83%
Synonyms: 1-NA-PP 1 hydrochloride
Target:  

Src PKD

1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of src family kinases and Protein Kinase D. 1-Naphthyl PP1 hydrochloride inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10943
CAS No.: 839706-07-9
Purity:  99.70%
Target:  

Bcr-Abl Ack1

Research Areas:  

Cancer

GNF-7 is a multikinase inhibitor. GNF-7 is a Bcr-Abl inhibitor, with IC50s of 133 nM and 61 nM for Bcr-Abl WT and Bcr-Abl T315I, respectively. GNF-7 also possesses inhibitory activity against both ACK1 (activated CDC42 kinase 1) and GCK (germinal center kinase) with IC50s of 25 nM and 8 nM, respectively. GNF-7 can be used for the research of hematologic malignancies .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-137460
CAS No.: 1388803-90-4
Purity:  99.85%
Synonyms: K0706
Target:  

Bcr-Abl

Research Areas:  

Cancer

Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research . Vodobatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...